Difference between revisions of "Ureteral Stent"

From DolceraWiki
Jump to: navigation, search
(→‎Dolcera Dashboard)
 
(262 intermediate revisions by 6 users not shown)
Line 1: Line 1:
−
== Ureteral Stent: Concept ==
+
'''This is a landscape report on the Ureteral stent market, including key company profiles, products, patents and relevant clinical trials.
−
An antimicrobial ureteral stent, which inhibits encrustation and bacterial colonization while maintaining patient comfort.
+
'''
  
 +
*'''''What is it?''''' A ureteral stent is a specially designed hollow tube, made of a flexible plastic material that is placed in the ureter.
 +
 +
*'''''Need for a ureteral stent:''''' In patients who have, or might have, an obstruction (blockage) of the kidney, an internal drainage tube called a ‘stent’ is commonly placed in the ureter, the tube between the kidney and the bladder. This is placed there in order to prevent or temporarily relieve the obstruction.
 +
 +
==Background==
 +
[[Image:Ureteral_Stent.png|thumb|200px|<center>[http://www.pnnmedical.com/urology/professionals/products/memokath%E2%84%A2-051-ureter.aspx '''Ureteric Stent''']</center>]]
 +
 +
Ureteral stents are used in urological surgery to maintain patency of the ureter to allow urine drainage from the renal pelvis to the bladder. These devices can be placed by a number of different endourological techniques. They are typically inserted through a cystoscope and may also be inserted intraoperatively. Indwelling ureteral stents help to reduce complications and morbidity subsequent to urological and surgical procedures. Frequently, ureteral stents are used
 +
to facilitate drainage in conjunction with Extracorporeal Shock Wave Lithotripsy (ESWL) and after endoscopic procedures. They are also used to internally support anastomoses and prevent urine leakage after surgery. Ureteral stenting may almost eliminate the urological complications of renal transplantation.
 +
An antimicrobial ureteral stent, which inhibits encrustation and bacterial colonization while maintaining patient comfort.
 
* Ureteral stent: resists migration, resists fragmentation, is kink resistant and radiopaque.
 
* Ureteral stent: resists migration, resists fragmentation, is kink resistant and radiopaque.
 
* Bacterial colonization: antimicrobial activity for up to two weeks.
 
* Bacterial colonization: antimicrobial activity for up to two weeks.
−
* Patient Comfort: stent has a low coefficient of fiiction (value) for ease of insertion and will soften on implant at body temperature to maintain patient comfort.
+
* Patient Comfort: stent has a low coefficient of friction (value) for ease of insertion and will soften on implant at body temperature to maintain patient comfort.
  
−
== Background ==
+
'''[[more on background...]]'''
−
Ureteral stents are used in urological surgery to maintain patency of the ureter to allow urine drainage from the renal pelvis to the bladder. These devices can be placed by a number of different endourological techniques. They are typically inserted through a cystoscope and may also be inserted intraoperatively. Indwelling ureteral stents help to reduce complications and morbidity subsequent to urological and surgical procedures. Frequently, ureteral stents are used to facilitate drainage in
+
−
conjunction with Extracorporeal Shock Wave Lithotripsy (ESWL) and after endoscopic procedures. They are also used to internally support anastomoses and prevent urine leakage after surgery. Ureteral stenting may almost eliminate the urological complications of renal transplantation.  
+
  
−
The advent of ESWL and the more recent barrage of endourological techniques have increased the indications for ureteral stents (Candela and Bellman 1997). Indications for use include:
+
=Market Overview=
−
* Treatment of ureteral or kidney stones
+
−
* Ureteral trauma or stricture
+
−
* Genitourinary reconstructive surgery
+
−
* Hydronephrosis during pregnancy
+
−
* Obstruction due to malignancy
+
−
* Retroperitoneal fibrosis
+
  
−
The need for ureteral stents range from a few days to several months. For patients with serious urological problems, ureteral stent maintenance may become a life-long necessity. Unfortunately, there are many problems associated with using ureteral stents.
+
Market for ureteral stent can be analyzed by estimating market for each of Ureteral Stent’s fundamental use. Other uses of Ureteral Stent include Post-surgical swelling/infection of uterus, Active kidney infection etc.
  
−
=== Ureteric stenting difficulties ===
+
'''[[more on market overview...]]'''
−
[[Image:Ureteral stent.jpg|thumb|right|350px|Double-J and Pigtail ureteral stents]]
+
−
{|border="2" cellspacing="2" cellpadding="4" width="50%"
+
−
|align = "center" bgcolor = "#00CCFF"|<font color="#993366">'''Common'''</font>
+
−
|align = "center" bgcolor = "#00CCFF"|<font color="#993366">'''Rare'''</font>
+
  
 +
=Interactive Mind Map=
 +
* To access the Dashboard you have to signup. You can do so by clicking [https://www.dolcera.com/auth/index.php/login '''here''']
 +
*''Use the mouse(click and drag/scroll up or down/click on nodes) to explore nodes in the detailed taxonomy''
 +
*''Click on the red arrow adjacent to the node name to view the content for that particular node in the dashboard''
 +
*''Click on the "+" sign to zoom the mindmap and "-" sign to shrink the mindmap''
 +
{|border="2" cellspacing="0" cellpadding="4" width="100%"
 +
 +
|<mm>[[Ureteral_Stent_Patent_Categorization.mm|flash|Patent Categorization|600pt]]</mm>
 +
 +
|}
 +
 +
=Patents=
 +
 +
 +
==Patent Search Strategy==
 +
[[Image:Patent Search Strategy.jpg|700px]]
 +
 +
 +
 +
== Dolcera Dashboard ==
 +
 +
 +
'''Dashboard Link'''<br>
 +
{|border="2" cellspacing="0" cellpadding="4" width="100%"
 +
|'''[https://www.dolcera.com/auth/dashboard/dashboard.php?workfile_id=1008 Ureteral Stent - Dashboard] '''
 +
|width="100"|[[Image:dashboard_thumb.png|center|100px|]]
 
|-
 
|-
−
|
 
−
* Trigonal irritation
 
−
* Haematuria
 
−
* Fever
 
−
* Infection
 
−
* Tissue inflammation
 
−
* Encrustation
 
−
* Biofilm formation
 
−
|
 
−
* Obstruction
 
−
* Kinking
 
−
* Ureteric rupture
 
−
* Ureteric perforation
 
−
* Stent misplacement
 
−
* Stent migration
 
−
* Stent misfit
 
−
* Stent forgotten
 
−
* Tissue hyperplasia
 
 
|}
 
|}
 +
*Flash Player is essential to view the Dolcera Dashboard
 +
* To access the Dashboard you have to signup. You can do so by clicking [https://www.dolcera.com/auth/index.php/login '''here''']
  
−
Today, elastomeric materials, such as silicones, polyurethanes and hydrogel-coated polyolefins are used, with no clear winner, which can withstand the urinary environment.
+
= Clinical Trials =
−
* Although silicone has better long-term stability than other stent materials, its extreme flexibility makes it difficult to pass over guidewires and through narrow or tortuous ureters.
+
−
* Polyethylene is stiffer and easier to use for patients with strictures; however, it has been known to become brittle with time leading to breakage and is no longer commercially available. * Polyurethane has properties that fall in between polyethylene and silicone; however, stent fracture also has been an issue with polyurethanes.
+
  
−
Attempts have been made to develop polymers with a combination of the best of all properties. The key players are C-Flex (Concept Polymer Technologies), Silitek and Percuflex (Boston Scientific).
+
==New trials ==
−
* C-Flex is proprietary silicone oil and mineral oil interpenetrated into a styrenelolefin block copolymer with the hope of reduced encrustation.
+
−
* Silitek (Medical Engineering Corporation) is another silicone-based copolymer.
+
−
* Percuflex is a proprietary olefinic block copolymer.
+
  
−
Metallic stents have been used recently to treat extrinsic ureteric obstructions. The effect of synthetic polymers on the urothelium of the urinary tract seems to be dependent on the bulk chemical composition of the polymer, the chemical composition of its surface, coatings on the device
+
{|border "1" style="border-spacing:0;"
−
surface, smoothness of the surface and coefficient of friction.
+
| style="background-color:#4f81bd;padding:0.079cm;"|<center><font color="#FFFFFF">'''S.No. '''</font></center>
 +
| style="background-color:#4f81bd;padding:0.079cm;"| <center><font color="#FFFFFF">'''Title '''</font></center>
 +
| style="background-color:#4f81bd;padding:0.079cm;"|<center><font color="#FFFFFF">'''Conditions '''</font></center>
 +
| style="background-color:#4f81bd;padding:0.079cm;"| <center><font color="#FFFFFF">'''Intervention: Device'''</font></center>
 +
| style="background-color:#4f81bd;padding:0.079cm;"| <center><font color="#FFFFFF">'''Sponsors and Collaborators '''</font></center>
 +
|-
 +
| style="background-color:#dce6f1;padding:0.079cm;"| <center>1</center>
 +
| style="background-color:#dce6f1;padding:0.079cm;"| [http://clinicaltrials.gov/ct2/show/NCT00250406?term=ureteral+stent&rank=1 Assessment of Drug-Eluting Ureteral Stent on Bacterial Adherence and Biofilm Formation]
 +
| style="background-color:#dce6f1;padding:0.079cm;"|Renal Calculi, Ureteral Obstruction
 +
| style="background-color:#dce6f1;padding:0.079cm;"| Ureteral Stent
 +
| style="background-color:#dce6f1;padding:0.079cm;"| Lawson Health Research Institute, Boston Scientific Corporation
 +
|-
 +
| style="padding:0.079cm;"| <center>2</center>
 +
| style="padding:0.079cm;"| [http://clinicaltrials.gov/ct2/show/NCT00270504?term=urethral+stent&rank=1 Memokath® 044TW Stent for Treatment of Urethral Stricture]
 +
| style="padding:0.079cm;"| Urethral Stricture
 +
| style="padding:0.079cm;"| Memokath stenting
 +
| style="padding:0.079cm;"| Engineers & Doctors Wallsten Medical Group
 +
|-
 +
| style="background-color:#dce6f1;padding:0.079cm;"| <center>3</center>
 +
| style="background-color:#dce6f1;padding:0.079cm;"|[http://clinicaltrials.gov/ct2/show/NCT00581178?term=urologic+stent&rank=3 Study to Determine if There Are Specific Clinical Factors to Determine Stent Encrustation]
 +
| style="background-color:#dce6f1;padding:0.079cm;"| Kidney Stones
 +
| style="background-color:#dce6f1;padding:0.079cm;"| N\A
 +
| style="background-color:#dce6f1;padding:0.079cm;"| University of California, Irvine
 +
|-
 +
| style="padding:0.079cm;"| <center>4</center>
 +
| style="padding:0.079cm;"| [http://clinicaltrials.gov/ct2/show/NCT00288457?term=urologic+stent&rank=14 Ureteral Stent Length and Patient Symptoms]
 +
| style="padding:0.079cm;"| Kidney Stones
 +
| style="padding:0.079cm;"| Ureteral Stent
 +
| style="padding:0.079cm;"| Emory University
 +
|-
 +
| style="background-color:#dce6f1;padding:0.079cm;"| <center>5</center>
 +
| style="background-color:#dce6f1;padding:0.079cm;"| [http://clinicaltrials.gov/ct2/show/NCT00166361?term=urologic+stent&rank=1 Drainage of Malignant Extrinsic Ureteral Obstruction Using the Memokath Ureteral Stent]
 +
| style="background-color:#dce6f1;padding:0.079cm;"| Ureteral Obstruction
 +
| style="background-color:#dce6f1;padding:0.079cm;"|Memokath 051 Ureteral Stent
 +
| style="background-color:#dce6f1;padding:0.079cm;"| Mayo Clinic Engineers & Doctors Wallsten Medical Group
 +
|-
 +
| style="padding:0.079cm;"| <center>6</center>
 +
| style="padding:0.079cm;"| [http://clinicaltrials.gov/ct2/show/NCT00739284?term=urologic+stent&rank=15 A Prospective Comparison Between Ureteral Stent and Nephrostomy Tube for an Urgent Drainage of Obstructed Kidney (JJVsPCN08)]
 +
| style="padding:0.079cm;"| Kidney Disease
 +
| style="padding:0.079cm;"| Nephrostomy tube and ureteral stent
 +
| style="padding:0.079cm;"| Rabin Medical Center
 +
|}
  
−
Typically, most ureteral stents are made of relatively smooth catheters. [http://www.ncbi.nlm.nih.gov/pubmed/10772512 Koleski et al., (2000)] tested a longitudinally grooved ureteral stent made by Circon in the pig ureter. The results indicated that the grooved stent led to better drainage than a conventional stent. Their opinion is that the ureter wall has a better chance of collapsing over a
+
== Concluded trials ==
−
smooth surface than a grooved surface, especially when debris is present. Stoller (2000) had the same experience with the SpiraStent(Urosurge Corp.). This helical stent was superior at passing stones than a conventional smooth stent.
+
{| {{table}}
 +
| style="background-color:#4f81bd;padding:0.079cm;"|<center><font color="#FFFFFF">'''S.No. '''</font></center>
 +
| style="background-color:#4f81bd;padding:0.079cm;"|<center><font color="#FFFFFF">'''Title'''</font></center>
 +
| style="background-color:#4f81bd;padding:0.079cm;"|<center><font color="#FFFFFF">'''Abstract'''</font></center>
 +
| style="background-color:#4f81bd;padding:0.079cm;"|<center><font color="#FFFFFF">'''Enrollment'''</font></center>
 +
| style="background-color:#4f81bd;padding:0.079cm;"|<center><font color="#FFFFFF">'''Disorder'''</font></center>
 +
| style="background-color:#4f81bd;padding:0.079cm;"|<center><font color="#FFFFFF">'''Conclusion'''</font></center>
 +
|-
 +
| style="background-color:#dce6f1;padding:0.079cm;"|<center>1</center>
 +
| style="background-color:#dce6f1;padding:0.079cm;"| Long-term outcome of permanent urethral stents in the treatment of detrusor-sphincter dyssynergia || style="background-color:#dce6f1;padding:0.079cm;"|To evaluate the long-term efficacy of a permanently implanted urethral stent in the treatment of spinally injured patients with detrusor-sphincter dyssynergia.|| style="background-color:#dce6f1;padding:0.079cm;"|13|| style="background-color:#dce6f1;padding:0.079cm;"|Detrusor-sphincter dyssynergia|| style="background-color:#dce6f1;padding:0.079cm;"|Stenting is an effective alternative to sphincterotomy in the long-term, although secondary bladder neck obstruction is a frequent problem.
 +
|-
 +
| style="padding:0.079cm;"| <center>2</center>
 +
| Nephrostomy Tube or 'JJ' Ureteric Stent in Ureteric Obstruction: Assessment of Patient Perspectives Using Quality-of-Life Survey and Utility Analysis||Upper urinary tract obstruction is often relieved by either a percutaneous nephrostomy tube (PCN) or a ureteric stent. Both can cause considerable morbidity and reduce patient's health-related quality of life (QoL). We have compared the QoL in these 2 groups.||34||Upper urinary tract obstruction||Patients with 'JJ' stents have significantly more irritative urinary symptoms and a high chance of local discomfort than patients with nephrostomy tubes (PCN). However, based on the EuroQol analysis, there is no significant difference in the gross impact on the health-related QoL or the utility between these groups indicating no patient preference for either modality of treatment.
 +
|-
 +
| style="background-color:#dce6f1;padding:0.079cm;"| <center>3</center>
 +
| style="background-color:#dce6f1;padding:0.079cm;"| Impact of stents on urological complications and health care expenditure in renal transplant recipients: results of a prospective, randomized clinical trial.|| style="background-color:#dce6f1;padding:0.079cm;"|A randomized, prospective trial to compare the incidence of early urological complications and health care expenditures in renal transplant recipients with or without ureteral stenting.|| style="background-color:#dce6f1;padding:0.079cm;"|201|| style="background-color:#dce6f1;padding:0.079cm;"|Renal transplant recipient|| style="background-color:#dce6f1;padding:0.079cm;"|Using a ureteral stent at renal transplantation significantly decreases the early urinary complications of urine leakage and obstruction. However, there is a significant increase in urinary tract infections, primarily beyond 30 days after transplantation. Stent removal within 4 weeks of insertion appears advisable.
 +
|}
  
−
There are a variety of ureteral stent configurations with different anchoring systems. Most stents today have a double [http://linkinghub.elsevier.com/retrieve/pii/S014067360002674X pigtail anchoring system]. (Tolley, 2000), Dunn et al, (2000) conducted a randomized, single-blind study comparing a Tail stent (proximal pigtail with a shaft which tapers to a lumenless straight tail) to a double pigtail stent. The Tail stent was found to be better tolerated than the double-pigtail concerning
 
−
lower urinary tract irritative symptoms. A double-J ureteral stent and a flexible ureteropyeloscope are shown in the first diagram. The other two diagrams show a pigtail ureteral stent in place; the end of the pigtail is facing away fiom the ureteral opening in the second of these two diagrams.
 
  
−
Early adverse effects of ureteral stenting include lower abdominal pain, dysuria, fever, urinary frequency, nocturia and hematuria. Patient discomfort and microscopic hematuria happen often. Major late complications include stent migration, stent fragmentation or more serious hydronephrosis with flank pain and infections.
 
  
−
Late complications occurred in one third of the patients in a prospective study using both silicone and polyurethane double pigtail stents (110 stents) in 90 patients. Stent removal was necessary in these patients. Others also have found this percentage of late complications. Device-related urinary tract infection and encrustation can lead to significant morbidity and even death and are the primary factors limiting long-term use of indwelling devices in the urinary tract. Microbial biofilm and encrustation may lead to stone formation. This is typically not a problem when stents are used
+
==Pre-Market Notification==
−
for short-term indications. Problems of biofilm formation, encrustation and stent fracture occur in patients with long-term indwelling stents.
+
  
−
Typically, manufacturers advise periodic stent evaluation. Cook polyurethane stent removal is recommend at 6 months and 12 months for silicone (Cook product literature). However, stents that are intended for long-term use are usually changed at regular intervals, as frequently as every 3 months.
+
Some of the companies active in the field of ureteral stents have been represented in the table below.  
  
−
Forgotten stents are a problem. Monga et al., 1995 found that 68% of stents forgotten more than 6 months were calcified and 10% were fragmented. Multiple urologic procedures were necessary to remove the stones. Long-term effects of these forgotten stents may lead to voiding dysfunction and renal insufficiency. Schlick, et al., 1998 are developing a biodegradable stent that will preclude the need for stent removal.  
+
{| border="2" cellspacing="0" cellpadding="4" width="100%"
 +
| style="background-color:#4f81bd;padding:0.079cm;"|<center><font color="#FFFFFF">'''S.No. '''</font></center>
 +
| style="background-color:#4f81bd;padding:0.079cm;"|<center><font color="#FFFFFF">'''Company '''</font></center>
 +
| style="background-color:#4f81bd;padding:0.079cm;"| <center><font color="#FFFFFF">'''Device '''</font></center>
 +
| style="background-color:#4f81bd;padding:0.079cm;"| <center><font color="#FFFFFF">'''Approval '''</font></center>
 +
| style="background-color:#4f81bd;padding:0.079cm;"| <center><font color="#FFFFFF">'''Date of Approval '''</font></center>
 +
| style="background-color:#4f81bd;padding:0.079cm;"| <center><font color="#FFFFFF">'''Material '''</font></center>
 +
| style="background-color:#4f81bd;padding:0.079cm;"| <center><font color="#FFFFFF">'''Technology '''</font></center>
 +
| style="background-color:#4f81bd;padding:0.079cm;"| <center><font color="#FFFFFF">'''Indwelling Time (days) '''</font></center>
 +
|-
 +
| style="background-color:#dce6f1;padding:0.079cm;"| <center>'''1'''</center>
 +
| style="background-color:#dce6f1;padding:0.079cm;"| <center>[http://www.bardurological.com/products/categoryTwo.aspx?bUnitID=3&catOneID=71 Bard Urological]</center>
 +
| style="background-color:#dce6f1;padding:0.079cm;"| <center>[[Image:InLay_Optima.png|thumb|center|100px|<center>InLay Optima</center>|[http://www.bardurological.com/products/loadProduct.aspx?bUnitID=3∏ID=225 <center>InLay Optima</center>]]]
 +
| style="background-color:#dce6f1;padding:0.079cm;"| <center>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=16869 FDA 510(k)]</center>
 +
| style="background-color:#dce6f1;padding:0.079cm;"| <center>Dec 2004</center>
 +
| style="background-color:#dce6f1;padding:0.079cm;"| Silicone
 +
| style="background-color:#dce6f1;padding:0.079cm;"| Double pigtail with monofilament suture loop
 +
| style="background-color:#dce6f1;padding:0.079cm;"| <center>365</center>
 +
|-
 +
| style="padding:0.079cm;"| <center>'''2'''</center>
 +
| style="padding:0.079cm;"| <center>[http://www.bostonscientific.com/Device.bsci/,,/method/DevHome/navRelId/1000.1003/seo.serve Boston Scientific]</center>
 +
| style="padding:0.079cm;"| [[Image:Polaris_Loop.png|thumb|center|100px|[http://www.bostonscientific.com/urology-stone/product.html?method=product_detail∏uct_id=10122561#initialLoad1() <center>Polaris Loop</center>]]]
 +
| style="padding:0.079cm;"| <center>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=10929 FDA 510(k)]</center>
 +
| style="padding:0.079cm;"| <center>Mar 2003</center>
 +
| style="padding:0.079cm;"| Dual Durometer Percuflex with HydroPlus Coating
 +
| style="padding:0.079cm;"| Bladder loop design
 +
| style="padding:0.079cm;"| <center>365</center>
 +
|-
 +
| style="background-color:#dce6f1;padding:0.079cm;"| <center>'''3'''</center>
 +
| style="background-color:#dce6f1;padding:0.079cm;"| <center>[http://www.cookmedical.com/uro/familyListingAction.do?family=Ureteral+Stents Cook Medical]</center>
 +
| style="background-color:#dce6f1;padding:0.079cm;"| [[Image:Resonance.png|thumb|center|100px|[http://www.cookmedical.com/uro/dataSheet.do?id=4418 <center>Resonance</center>]]]
 +
| style="background-color:#dce6f1;padding:0.079cm;"| <center>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=23620 FDA 510(k)]</center>
 +
| style="background-color:#dce6f1;padding:0.079cm;"| <center>May 2007</center>
 +
| style="background-color:#dce6f1;padding:0.079cm;"| Metal
 +
| style="background-color:#dce6f1;padding:0.079cm;"| Temporary stenting
 +
| style="background-color:#dce6f1;padding:0.079cm;"| <center>365</center>
 +
|-
 +
| style="padding:0.079cm;" rowspan="2"| <center>'''4'''</center>
 +
| style="padding:0.079cm;" rowspan="2"| <center>[http://www.fossamedical.com/news.htm Fossa Medical]</center>
 +
| style="padding:0.079cm;" rowspan="2"| [[Image:Stone_Sweeper.png|thumb|center|100px|[http://dolcera.com/upload/files/stonesweeper_fossa_trial.pdf <center>Stone Sweeper</center>]]]
 +
| style="padding:0.079cm;"| <center>[http://www.fossamedical.com/news.htm FDA 510(k)]</center>
 +
| style="padding:0.079cm;"| <center>Aug 2002</center>
 +
| style="padding:0.079cm;" rowspan="2"| Polyurethane
 +
| style="padding:0.079cm;" rowspan="2"| Spiral radially expanding stent
 +
| style="padding:0.079cm;" rowspan="2"| <center>13</center>
 +
|-
 +
| style="padding:0.079cm;"| <center>[http://www.fossamedical.com/news.htm CE Mark]</center>
 +
| style="padding:0.079cm;"| <center>Sep 2005</center>
  
−
==== Encrustation ====
+
|-
−
The urinary system presents a challenge because of its chemically unstable environment. Long-term biocompatibility and biodurability of devices have been problems due to the supersaturation of uromucoids and crystalloids at the interface between urine and the device. Encrustation of ureteral stents is a well-known problem, which can be treated easily if recognized early. However, severe encrustation leads to renal failure and is difficult to manage (Mohan-Pillai et al., 1999). All biomaterials currently used become encrusted to some extent when exposed to urine.
+
| style="background-color:#dce6f1;padding:0.079cm;"| <center>'''5'''</center>
 +
| style="background-color:#dce6f1;padding:0.079cm;"| <center>[http://www.pnnmedical.com/urology/professionals/products/memokath™-051-ureter.aspx Pnn Medical A/S]</center>
 +
| style="background-color:#dce6f1;padding:0.079cm;"| [[Image:Memokath_051.png|thumb|center|100px|[http://www.google.com/url?sa=t&source=web&cd=4&ved=0CC4QFjAD&url=http://www.hammer.pl/pliki/147_2.pdf&rct=j&q=memokath%20051&ei=MfhATezNIoaqvQP-_ZGtAw&usg=AFQjCNFR-ZFsu33rk6B9Flq1tCsYBZyXMw&cad=rja <center>Memokath 051</center>]]]
 +
| style="background-color:#dce6f1;padding:0.079cm;"| <center>[http://www.pnnmedical.com/about-pnn-medical/company-history.aspx CE Mark]</center>
 +
| style="background-color:#dce6f1;padding:0.079cm;"| <center>1995</center>
 +
| style="background-color:#dce6f1;padding:0.079cm;"| Nickel-titanium shape memory alloy
 +
| style="background-color:#dce6f1;padding:0.079cm;"| Double fluted ended spiral stent
 +
| style="background-color:#dce6f1;padding:0.079cm;"| <center>240</center>
 +
|}
  
−
The encrusted deposits can harbor bacterial biofilms. In addition, they can render the biomaterial brittle which causes fracture in-situ, a serious problem especially associated with the use of polyethylene and polyurethane ureteral stents (although silicone stents have also been
+
=Products=
−
reported to fracture). Stent fragments can migrate to the bladder or renal pelvis with serious repercussions.
+
  
−
Surface science techniques were used to study three stent types after use in patients. The stent type, duration of insertion and age or sex of the patient did not correlate significantly with the amount of encrustation (Wollin et al., 1998). However, it has been suggested that factors which affect the amount of encrustation include the composition or the urine, the type of invading and colonizing bacteria and the structure and surface properties of the biomaterial used (Gorman 1995). A low surface energy surface seems to resist encrustation compared with a high surface energy surface (Denstedt et al., 1998).
+
The FDA classifies a ureteric stent as follows:
 +
* TITLE 21      - FOOD AND DRUGS
 +
* CHAPTER I      - FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES
 +
* SUBCHAPTER H  - MEDICAL DEVICES
 +
* PART 876      - GASTROENTEROLOGY-UROLOGY DEVICES
 +
* Subpart E      - Surgical Devices
 +
* Sec. 876.4620  - Ureteral stent.  
 +
* Classification - class II device [http://www.accessdata.fda.gov/SCRIPTS/cdrh/cfdocs/cfCFR/CFR.cfm?fr=876.4620&Term=ureter%20stent Code of Federal Regulations]
  
−
Many different types of stone can form in the urinary tract. Calcium oxalate, calcium phosphate, uric acid and cystine stones are metabolic stones because they form as a result of metabolic dysfunction. They usually are excreted from the urinary tract. Struvite (magnesium ammonium phosphate) and hydroxyapatite (calcium phosphate) are associated with infection (infection stones). These account for 1520% of urinary calculi. ESWL is used to break up the larger infection stones because they don't pass; recurrence of the problem occurs with incomplete removal. Infection stones can manifest as poorly mineralized matrix stones, highly mineralized staghorn calculi or as bladder stones which often form in the presence of ureteral stents. Urea-splitting bacteria colonize the surface and cause alkalinization of the urine, which lowers
+
{|border="2" cellspacing="0" cellpadding="4" width="100%"
−
the solubility of struvite and hydroxyapatite, and they deposit on the
+
|align = "center" bgcolor = "#4f81bd"|'''Sr. No.'''
−
surface. Bacterial biofilm associated with encrustation is a common
+
|align = "center" bgcolor = "#4f81bd"|'''Company'''
−
clinical occurrence. (Gorman and Tunney, 1997). It has been suggested
+
|align = "center" bgcolor = "#4f81bd"|'''Device(s)'''
−
that prevention of bacterial colonization would prevent encrustation
+
|align = "center" bgcolor = "#4f81bd"|'''Approval'''
−
because of their ultimate responsibility for its formation (Bibby et al.,
+
|align = "center" bgcolor = "#4f81bd"|'''Approval Date'''
−
1995).
+
|align = "center" bgcolor = "#4f81bd"|'''Material'''
−
An in vitro model was developed that produces encrustation
+
|bgcolor = "#4f81bd"|'''Technology'''
−
similar to those seen in vivo (Tunney et al., 1996a). An experiment was
+
|align = "center" bgcolor = "#4f81bd"|'''Indwelling Time (days)'''
−
conducted to compare the encrustation potential of various ureteral stent
+
|align = "center" bgcolor = "#4f81bd"|'''Image'''
−
materials. The long-term struvite and hydroxyapatite encrustation of
+
|-
−
silicone, polyurethane, hydrogel-coated polyurethane, Silitek and
+
|align = "center" bgcolor = "#dce6f1"|'''1'''
−
Percuflex were compared. All of the materials developed encrustation,
+
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.allium-medical.com/?categoryId=64772 Allium, Israel]</u></font>
−
however, it was found by image analysis that the rates of encrustation
+
|align = "center" bgcolor = "#dce6f1"|[http://www.allium-medical.com/?categoryId=64772 URS]
−
varied on the different materials. Silicone had less encrustation (69% at
+
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF">[http://www.highbeam.com/doc/1G1-165990208.html CE Mark]</font>
−
10 weeks) compared to the other materials (1 00%) at the same time point
+
|align = "center" bgcolor = "#dce6f1"|Jul, 2007
−
(Tunney et al., 1996b). Continuous flow models have also been developed
+
|bgcolor = "#dce6f1"|Nickel-titanium shape memory alloy covered by polymer
−
which are more representative of conditions in the upper urinary tract.
+
|bgcolor = "#dce6f1"|Self-expanding stent
−
They are discussed by Gorman and Tunney, (1 997).
+
|align = "center" bgcolor = "#dce6f1"|
−
Efforts to reduce encrustation using new materials, smoother
+
|bgcolor = "#dce6f1"|[[Image:656px-Allium.jpg|thumb|center|100px|<center>Allium</center>]]
−
surfaces and hydrogel coatings have been attempted. A hydrogel-coated
+
−
C-flex stent (Hydroplus, Boston Scientific) was shown to have less
+
−
epithelial cell damage and encrustation than other biomaterials and was
+
−
recommended by the investigators for long-term use (Cormio, 1995). In
+
−
addition, a poly(ethy1ene oxide)/polyurethane composite hydrogel
+
−
(Aquavenem, J & J) resisted intraluminal blockage in a urine flow model
+
  
−
compared with silicone and polyurethane (Gorman et al., 1997a). Another
+
|-
−
advantage with Aquavene is that it is rigid in the dry state, which
+
|align = "center" rowspan = "2"|'''2'''
−
facilitates insertion past obstructions in the ureter and becomes soft on
+
|align = "center" rowspan = "2"|<font color="#0000FF">[http://www.pnnmedical.com/urology/professionals/products/memokath™-051-ureter.aspx Pnn Medical A/S]</font>
−
hydration providing comfort (Gorman and Tunney, 1997). Gorman et al.
+
|align = "center" rowspan = "2"|[http://www.google.com/url?sa=t&source=web&cd=4&ved=0CC4QFjAD&url=http://www.hammer.pl/pliki/147_2.pdf&rct=j&q=memokath%20051&ei=MfhATezNIoaqvQP-_ZGtAw&usg=AFQjCNFR-ZFsu33rk6B9Flq1tCsYBZyXMw&cad=rja Memokath 051]
−
(1 997b) concluded that the chance of stent fracture would be reduced if
+
|align = "center"|<font color="#0000FF">[http://www.pnnmedical.com/about-pnn-medical/company-history.aspx CE Mark]</font>
−
the ureteral stent side holes were eliminated.
+
|align = "center"|1995
−
Urinary tract infection is another common major problem with the
+
|rowspan = "2"|Nickel-titanium shape memory alloy
−
usage of ureteral stents. Initially, a conditioning film is deposited on the
+
|rowspan = "2"|Double fluted ended spiral stent
−
ureteral stent surface. The film is made up of proteins, electrolyte
+
|align = "center" rowspan = "2"|240
−
materials and other unidentified materials that obscure the surface
+
|rowspan = "2"|[[Image:Memokath_051.png|thumb|center|100px|<center>Memokath 051</center>]]
−
properties of the stent material. Electrostatic interactions, the ionic
+
−
strength and pH of the urine and differences in fluid surface tensions affect
+
−
bacterial adhesion to the conditioning film. Subsequently, a microbial
+
−
biofilm forms over time. The biofilm is composed of bacterial cells
+
−
embedded in a hydrated, predominantly anionic mixture of bacterial
+
−
exopolysaccharides and trapped host extracellular macromolecules.
+
−
Obstruction of urine flow and urinary tract sepsis can result in continued
+
−
growth of the biofilm. Colonization of devices implanted in the urinary
+
−
tract can lead to dysfunction, tissue intolerance, pain, subclinical or overt
+
−
infection and even urosepsis. Device related infections are difficult to
+
−
treat and device removal is usually necessary. The biofilm has been found
+
−
to impede the diffusion of antibiotics; in addition, the bacteria in the
+
−
biofilm have a decreased metabolic rate , which also protects them against
+
−
the effects of antibiotics (Wollin et al., 1998).
+
−
Riedl, et al. (1 999) found 100% ureteral stent colonization rates in
+
−
permanent and 69.3% in temporary stents. Antibiotic prophylaxis did not
+
−
prevent bacterial colonization and it was recommended that it not be used.
+
−
On the other hand, Tieszer, et al. (1 998) believe that fluoroquinolones can
+
−
prevent infection. They also have found that some stents have denser
+
−
encrustation than others, however, the stent material did not change the
+
−
elements of the "conditioning film" adsorbed or alter its receptivity to
+
−
bacterial biofilms.
+
−
The predictive value of urine cultures in the assessment of stent
+
−
colonization was examined in 65 patients with indwelling ureteral stents.
+
−
It was found that a sterile urine culture did not rule out the stent itself
+
−
being colonized (Lifshitz, et al., 1999). Patients with sterile urine culture
+
−
may benefit from prophylactic antibiotics; however, the authors contended
+
−
that the antibiotics must work against gram-negative uropathogens and
+
−
gram-positive bacteria including enterococci.
+
−
It is obvious that there is controversy in the literature whether
+
−
prophylactic systemic antibiotics are useful with ureteral stent implant.
+
−
However, antibiotics do not seem to prevent stent colonization. Denstedt
+
−
et al. (1998) have found that ciprofloxacin, with a 3 day burst every 2
+
−
weeks, actually is adsorbed onto the stent which makes longer term
+
−
treatment possible with reduced risk of bacterial resistance. There has
+
−
been research targeted at coating or impregnating urinary catheters with
+
  
−
antimicrobials and products are on the market, however, there are no
+
|-
−
antimicrobial ureteral stents approved by the FDA.
+
|align = "center"|<font color="#0000FF"><u>[http://www.zapconnect.com/products/index.cfm/fuseaction/products_display_detail/eregnum/8021561/owner_operator_number/8021561/product_code/FAD/8021561.html FDA Listing]</u></font>
−
It is clear that there is a need for a new material that will be able to
+
|align = "center"|Mar, 2004
−
resist encrustation and infection in the urinary tract.
+
|-
−
According to Merrill Lynch, ureteral stents represent an $80 MM
+
|align = "center" bgcolor = "#dce6f1" rowspan = "5"|'''3'''
−
US market. Boston Scientific is in the lead with -50% of the market
+
|align = "center" bgcolor = "#dce6f1" rowspan = "5"|<font color="#0000FF"><u>[http://www.fossamedical.com/news.htm Fossa Medical]</u></font>
−
followed by Maxxim (Circon), Cook and Bard is a smaller player. There
+
|align = "center" bgcolor = "#dce6f1" rowspan = "2"|[http://dolcera.com/upload/files/stonesweeper_fossa_trial.pdf Stone Sweeper]
−
are a number of other small contenders.
+
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.fossamedical.com/news.htm CE Mark]</u></font>
−
The use of ureteral stents is increasing; the indications for ureteral
+
|align = "center" bgcolor = "#dce6f1"|Sep, 2005
−
stenting have broadened from temporary or permanent relief or ureteric
+
|bgcolor = "#dce6f1" rowspan = "2"|Polyurethane
−
obstruction to include temporary urinary diversion following surgical
+
|bgcolor = "#dce6f1" rowspan = "2"|Radially expanding stent
−
procedures such as endopyelotomy and ureteroscopy and facilitation of
+
|align = "center" bgcolor = "#dce6f1" rowspan = "2"|13
−
stone clearance after ESWL (Tolley, 2000). The use of ureteral stents for
+
|rowspan = "2" bgcolor = "#dce6f1"|[[Image:Stone_Sweeper.png|thumb|center|100px|<center>Stone Sweeper</center>]]
−
patients having ESWL for renal calculi is however controversial and
+
−
seems to be related to the size of the stones and invasiveness of the
+
−
procedure. According to survey results reported by Hollowell, et al.
+
−
(2000), there is a significant difference in opinion concerning the use of
+
−
stents with ESWL. The number of ureteral stents used in patients with
+
−
stones 2 cm or less treated with ESWL is significant in spite of the lack
+
−
scientific evidence in support of this practice. Of 1,029 urologists
+
−
returning surveys, for patients with renal pelvic stones 10, 15 or 20 rnm
+
−
treated with ESWL, routine stent placement was preferred by 25.3%,
+
−
57.1 % and 87.1 %, respectively. Urologists recommend using
+
−
ureteroscopy rather than ESWL for distal ureteral calculi 5-1 0 mm.
+
−
1.2 Fit with Gore Corporate Strategy
+
−
+ This product fits into Gore's DSP market segment
+
−
+ A family of products is needed to market through a distributor
+
−
+ A possible family of products includes ureteral stents, urethral
+
−
slings, urologic suture, urethral stents and urethral catheters
+
−
(Foley), renal artery stent?
+
−
+ It is preferable that a stand alone product be of high value
+
−
+ Gore is interested in exploiting PATT technology in products where
+
−
silicone and polyurethanes have not met expectations and where PATT
+
−
has potential product performance benefit
+
−
1.3 Prototypes
+
−
The amount of encrustation on PATT tubes (measured by weight
+
−
gain) was compared with that on silicone (Bard) and Percuflex (Boston
+
−
Scientific) catheters after being subjected to in vitro static and dynamicflow
+
−
synthetic urine models.
+
−
Static Model
+
−
Dried tube pieces were suspended in stirring synthetic urine for up
+
−
to 3 months. Samples were taken at 1,2 and 3 months at which time they
+
−
were dried and weighed. The results of this experiment can be found in a
+
−
graph of Absolute Weight Change vs Time in the Appendix. There are no
+
  
−
error bars because this was a destructive test and there was only one
+
|-
−
sample in each group. The PATT catheter was found to encrust to a lesser
+
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.fossamedical.com/news.htm FDA 510(k)]</u></font>
−
extent than the other catheters: 6 times less than the Boston Scientific stent
+
|align = "center" bgcolor = "#dce6f1"|Aug, 2002
−
and almost half as much as the Bard stent at two months. Note that the 1 -
+
 
−
%-.L month Bard data is in error because the sample broke during preparation
+
|-
−
& & and the lost segment was not recovered. The 3-month data is pending. In
+
|align = "center" bgcolor = "#dce6f1" rowspan = "2"|[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/PMNSimple.cfm?db=PMN&ID=K033368 Open lumen stent]
−
dA'eadndcrituiostna,t iSoEnM ons tahree cinacthluedteerd l uinm tihnea lA apnpde anbdliuxm, winhailc shu vrfisaucaelsi.z eT thhee SEMs
+
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/PMNSimple.cfm?db=PMN&ID=K033368 FDA 510(k)]</u></font>
−
suggest that PATT has a clean surface relative to the other two materials.
+
|align = "center" bgcolor = "#dce6f1"|Nov, 2003
−
Dynamic Model
+
|bgcolor = "#dce6f1" rowspan = "2"|Polyurethane
−
Straight pieces cut from the stents (approximately 4.5 cm) were
+
|bgcolor = "#dce6f1" rowspan = "2"|Pigtail-tipped stent with <nowiki>’</nowiki>Pusher<nowiki>’</nowiki>
−
attached to nozzles through which artificial urine passed from a reservoir.
+
|align = "center" bgcolor = "#dce6f1" rowspan = "2"|
−
"," @ The artificial urine was recirculated from the collecting tank to the P " " >
+
|align = "center" bgcolor = "#dce6f1" rowspan = "2"| [[Image:Open_Lumen.png|thumb|center|100px|<center>Open_lumen</center>]]
−
$4
+
 
−
reservoir. The experiment was run for two months. Unfortunately, the
+
|-
−
&/J' data from this experiment proved inconclusive. It appears that the nozzles were the weak link in this experiment as they were found to encrust which
+
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.fossamedical.com/news.htm CE Mark]</u></font>
−
..rp."e ;p"
+
|align = "center" bgcolor = "#dce6f1"|Sep, 2005
−
'
+
|-
−
led to the decreased flow rates through the test articles downstream. In
+
|align = "center" bgcolor = "#dce6f1"|[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/PMNSimple.cfm?db=PMN&ID=K021140 Expanding Ureteral Stent]
−
addition, the test articles were found to weigh less after the experiment
+
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/PMNSimple.cfm?db=PMN&ID=K021140 FDA 510(k)]</u></font>
−
than they did before, an artifact that is probably a result of the scale being
+
|align = "center" bgcolor = "#dce6f1"|Jun, 2002
−
moved and recalibrated while the experiment was ongoing.
+
|bgcolor = "#dce6f1"|Polyurethane
−
\L -
+
|bgcolor = "#dce6f1"|Double pigtail stent with <nowiki>’</nowiki>Pusher<nowiki>’</nowiki>
−
Ndm 2.0 Intellectual Property Assessment
+
|align = "center" bgcolor = "#dce6f1"|
−
Z3.L
+
|align = "center" bgcolor = "#dce6f1"| N/A
−
+ Will be verbally communicated at the meeting
+
 
−
3.0 Sales and Marketing Assessment
+
|-
−
3.1 Market Opportunities - - + Urological surgeons are the potential customers for the Gore ureteral
+
|align = "center" rowspan = "7"|'''4'''
−
stent.
+
|align = "center" rowspan = "7"|<font color="#0000FF"><u>[http://www.bostonscientific.com/Device.bsci/,,/method/DevHome/navRelId/1000.1003/seo.serve Boston Scientific]</u></font>
−
+ Merrill Lynch estimates the US market for ureteral stents is $80 MM
+
|align = "center"|<font color="#0000FF"><u>Contour</u></font>
−
and that Boston Scientific has -50% of the market. Steve Nordstrom
+
|align = "center"|
−
(worked at Boston Scientific for -10 years) believes that the Boston
+
|align = "center"|
−
Scientific US revenues are $38 MM with 70% of a $50 MM market.
+
|Percuflex - proprietary polyolefin copolymer; Hydroplus coating
−
+ It is very difficult to obtain an accurate estimate of the number of
+
|Fixed and variable length; Tapered tip
−
procedures using a ureteral stent. This is because temporary stents are
+
|align = "center"|365
−
not coded and therefore their use in a given procedure is not recorded.
+
|align = "center" |[[Image:Contour.png|thumb|center|100px|<center>Contour</center>]]
−
In 1998, MDI estimated that there were 212,000 procedures in the U.
+
|-
−
S. (corresponding revenue $26.5 MM). MDI would have had the same
+
|align = "center"|<font color="#0000FF"><u>Percuflex</u></font>
−
problem we encounter. The only hard data that Helene Johns is able to
+
|align = "center"|
−
obtain in which a stent definitely was used in the procedure is 147,000
+
|align = "center"|
−
inpatient ureteral catheterization procedures in 1999 from NIPS data.
+
|align = "center"| Percuflex
−
In the 1998 Outpatient Handbook, there were 7,003 cystoscopies with
+
|Pigtail
−
stone removal in which 30% of the time a ureteral stent placement
+
|align = "center"|365
−
occurred; there were 30,5 19 cystoscopies and ureteral catheterizations
+
|align = "center" |[[Image:Percuflex.png|thumb|center|100px|<center>Percuflex</center>]]
−
in which there were ureteral stents placed 6.3% of the time. This gives
+
|-
−
a total of 15 1,033 procedures. Based on information obtained from
+
|align = "center"|<font color="#0000FF"><u>Polaris Ultra</u></font>
 +
|align = "center"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/PMNSimple.cfm?db=PMN&id=K010002 FDA 510(k)]</u></font>
 +
|align = "center"|Jan, 2001
 +
|Dual Durometer Percuflex with HydroPlus Coating; soft Nautilus Bladder Coil.
 +
|Double pigtail
 +
|align = "center"|365
 +
|align = "center" |[[Image:Polaris_Ultra.png|thumb|center|100px|<center>Polaris Ultra</center>]]
 +
|-
 +
|align = "center"|<font color="#0000FF"><u>Polaris Loop</u></font>
 +
|align = "center"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=10929 FDA 510(k)]</u></font>
 +
|align = "center"|Mar, 2003
 +
|Dual Durometer Percuflex with HydroPlus Coating
 +
|Bladder loop design
 +
|align = "center"|365
 +
|align = "center" |[[Image:Polaris_Loop.png|thumb|center|100px|<center>Polaris Loop</center>]]
 +
|-
 +
|align = "center"|<font color="#0000FF"><u>[http://www.google.com/url?sa=t&source=web&cd=4&ved=0CCkQFjAD&url=http://www.bostonscientific.com/templatedata/imports/Microsite/Stone-EU/collateral/stone-eu-percuflex-brochure-eng.pdf&rct=j&q=percuflex%20brochure&ei=bIE-Tb79HMnqrAf5-_HRCA&usg=AFQjCNEJ-JOc Retromax Plus]</u></font>
 +
|align = "center"|
 +
|align = "center"|
 +
|Percuflex material and Hydroplus coating
 +
|Endopyelotomy stent
 +
|align = "center"|Post-procedure healing
 +
|align = "center" |[[Image:Retromax_plus.png|thumb|center|100px|<center>Retromax Plus</center>]]
 +
|-
 +
|align = "center"|<font color="#0000FF"><u>[http://www.google.com/url?sa=t&source=web&cd=4&ved=0CCkQFjAD&url=http://www.bostonscientific.com/templatedata/imports/Microsite/Stone-EU/collateral/stone-eu-percuflex-brochure-eng.pdf&rct=j&q=percuflex%20brochure&ei=bIE-Tb79HMnqrAf5-_HRCA&usg=AFQjCNEJ-JOc Stretch VL Flexima]</u></font>
 +
|align = "center"|
 +
|align = "center"|
 +
|Hydroplus Coating
 +
|Variable length coil on distal and proximal ends
 +
|align = "center"|90
 +
|align = "center" |[[Image:Stretch_VL_Flexima.png|thumb|center|100px|<center>Stretch VL Flexima</center>]]
 +
|-
 +
|align = "center"|[http://dolcera.com/upload/files/drug_eluting_ureteral_stent.pdf Drug-Eluting Stent]
 +
|align = "center"|
 +
|align = "center"|
 +
|Percuflex - proprietary polyolefin copolymer
 +
|Ketorolac trimethamine loaded stent
 +
|align = "center"|
 +
|align = "center"| N/A
 +
|-
 +
|align = "center" bgcolor = "#dce6f1" rowspan = "6"|'''5'''
 +
|align = "center" bgcolor = "#dce6f1" rowspan = "6"|<font color="#0000FF">[http://www.cookmedical.com/uro/familyListingAction.do?family=Ureteral+Stents Cook Medical]</font>
 +
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.cookmedical.com/uro/dataSheet.do?id=4418 Resonance]</u></font>
 +
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=23620 FDA 510(k)]</u></font>
 +
|align = "center" bgcolor = "#dce6f1"|May, 2007
 +
|bgcolor = "#dce6f1"|Metal
 +
|bgcolor = "#dce6f1"|
 +
|align = "center" bgcolor = "#dce6f1"|365
 +
|align = "center" bgcolor = "#dce6f1"|[[Image:Resonance.png|thumb|center|100px|<center>Resonance</center>]]
 +
|-
 +
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.cookmedical.com/uro/dataSheet.do?id=2055 Sof-flex]</u></font>
 +
|align = "center" bgcolor = "#dce6f1"|
 +
|align = "center" bgcolor = "#dce6f1"|
 +
|bgcolor = "#dce6f1"|AQ® Hydrophilic Coating
 +
|bgcolor = "#dce6f1"|Radiopaque tip and tether for repositioning
 +
|align = "center" bgcolor = "#dce6f1"|180
 +
|align = "center" bgcolor = "#dce6f1"|[[Image:Sof_flex.png|thumb|center|100px|<center>Sof-flex</center>]]
 +
|-
 +
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.cookmedical.com/uro/dataSheet.do?id=3627 Endo-Sof]</u></font>
 +
|align = "center" bgcolor = "#dce6f1"|
 +
|align = "center" bgcolor = "#dce6f1"|
 +
|bgcolor = "#dce6f1"|AQ® Hydrophilic Coating
 +
|bgcolor = "#dce6f1"|Double pigtail
 +
|align = "center" bgcolor = "#dce6f1"|365
 +
|align = "center" bgcolor = "#dce6f1"|[[Image:Endo_Sof.png|thumb|center|100px|<center>Endo-Sof</center>]]
 +
|-
 +
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.cookmedical.com/uro/dataSheet.do?id=3643 C-Flex]</u></font>
 +
|align = "center" bgcolor = "#dce6f1"|
 +
|align = "center" bgcolor = "#dce6f1"|
 +
|bgcolor = "#dce6f1"|
 +
|bgcolor = "#dce6f1"|Double Pigtail
 +
|align = "center" bgcolor = "#dce6f1"|180
 +
|align = "center" bgcolor = "#dce6f1"|[[Image:C_Flex.png|thumb|center|100px|<center>C-Flex</center>]]
 +
|-
 +
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.cookmedical.com/uro/dataSheet.do?id=4692 Smith Universal]</u></font>
 +
|align = "center" bgcolor = "#dce6f1"|
 +
|align = "center" bgcolor = "#dce6f1"|
 +
|bgcolor = "#dce6f1"|
 +
|bgcolor = "#dce6f1"|Nephrostomy tube <nowiki>+</nowiki> Ureteral stent
 +
|align = "center" bgcolor = "#dce6f1"|60
 +
|align = "center" bgcolor = "#dce6f1"|[[Image:Smith_Universal.png|thumb|center|100px|<center>Smith Universal</center>]]
 +
|-
 +
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.medicalnewstoday.com/articles/90717.php Endo-Sof Radiance]</u></font>
 +
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.medicalnewstoday.com/articles/90717.php Launch]</u></font>
 +
|align = "center" bgcolor = "#dce6f1"|Dec, 2007
 +
|bgcolor = "#dce6f1"|Heparin-bonded stent
 +
|bgcolor = "#dce6f1"|
 +
|align = "center" bgcolor = "#dce6f1"|
 +
|bgcolor = "#dce6f1"|
 +
|-
 +
|align = "center"|'''6'''
 +
|align = "center"|<font color="#0000FF">[http://qurological.com/product/ Q Urological]</font>
 +
|align = "center"|<font color="#0000FF"><u>[http://qurological.com/product/ pAguaMedicina™ Pediatric Ureteral Stent]</u></font>
 +
|align = "center"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=29056 FDA 510(k)]</u></font>
 +
|align = "center"|Jan, 2010
 +
|Hydrogel
 +
|Differentially larger end (no pigtail)
 +
|align = "center"|30
 +
|align = "center" |[[Image:pAguaMedicina.png|thumb|center|100px|<center>pAguaMedicina</center>]]
 +
|-
 +
|align = "center" bgcolor = "#dce6f1"|'''7'''
 +
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF">[http://www.bioteq.com.tw/en/products.php?kind=2&series=4 Bioteque Corp.]</font>
 +
|align = "center" bgcolor = "#dce6f1"|Ureteral Stent Set
 +
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.bioteq.com.tw/en/news_detail.php?id=1&query_string= FDA 510(k) ]</u></font>
 +
|align = "center" bgcolor = "#dce6f1"|Apr, 2010
 +
|bgcolor = "#dce6f1"|
 +
|bgcolor = "#dce6f1"|
 +
|align = "center" bgcolor = "#dce6f1"|30
 +
|align = "center" bgcolor = "#dce6f1"|[[Image:bioteque.png|thumb|center|100px|<center>Bioteque</center>]]
 +
|-
 +
|align = "center" rowspan = "4"|'''8'''
 +
|align = "center" rowspan = "4"|<font color="#0000FF">[http://www.appliedmed.com/products/product_card.aspx?section=professionals&proceGroupID=4&groupName=Urology&catID=37&Name=Ureteral+stents Applied Medical Resources, CA, USA]</font>
 +
|align = "center"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=4353 Mesh]</u></font>
 +
|align = "center"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=4353 FDA 510(k)]</u></font>
 +
|align = "center"|Jul, 2001
 +
|Polyester mesh
 +
|Double-pigtail
 +
|align = "center"|
 +
|align = "center"| N/A
 +
|-
 +
|align = "center"|<font color="#0000FF"><u>[http://www.appliedmed.com/products/product_card.aspx?section=professionals&proceGroupID=4&groupName=Urology&catID=37&Name=Ureteral+stents Silhouette ]</u></font>
 +
|align = "center"|
 +
|align = "center"|
 +
|Coil-reinforced; SL-6® hydrophilic coating
 +
|Patency Device
 +
|align = "center"|
 +
|align = "center" |[[Image:silhouette.png|thumb|center|100px|<center>Silhouette</center>]]
 +
|-
 +
|align = "center"|<font color="#0000FF"><u>[http://www.appliedmed.com/products/product_card.aspx?section=professionals&proceGroupID=4&groupName=Urology&catID=37&Name=Ureteral+stents Applied Standard]</u></font>
 +
|align = "center"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=124645 FDA 510(k)]</u></font>
 +
|align = "center"|Jun, 1999
 +
|Proprietary thermoplastic elastomer material; SL-6® hydrophilic coating
 +
|Unique wall construction and enlarged drainage holes
 +
|align = "center"|
 +
|align = "center" |[[Image:Applied_Std1.png|thumb|center|100px|<center>Applied Standard</center>]]
 +
|-
 +
|align = "center"|<font color="#0000FF"><u>[http://www.appliedmed.com/products/product_card.aspx?section=professionals&proceGroupID=4&groupName=Urology&catID=37&Name=Ureteral+stents 7-10 endopyelotomy]</u></font>
 +
|align = "center"|
 +
|align = "center"|
 +
|Proprietary thermoplastic elastomer material; SL-6® hydrophilic coating
 +
|Dual Diameter stent
 +
|align = "center"|
 +
|align = "center" |[[Image:Applied_7_10.png|thumb|center|100px|<center>Endopyelotomy Stent</center>]]
 +
|-
 +
|align = "center" bgcolor = "#dce6f1" rowspan = "6"|'''9'''
 +
|align = "center" bgcolor = "#dce6f1" rowspan = "6"|<font color="#0000FF"><u>[http://www.bardurological.com/products/categoryTwo.aspx?bUnitID=3&catOneID=71 Bard Urological]</u></font>
 +
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.bardurological.com/products/loadProduct.aspx?bUnitID=3&prodID=225 InLay Optima]</u></font>
 +
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=16869 FDA 510(k)]</u></font>
 +
|align = "center" bgcolor = "#dce6f1"|Dec, 2004
 +
|bgcolor = "#dce6f1"|Silicone
 +
|bgcolor = "#dce6f1"|Double pigtail with monofilament suture loop
 +
|align = "center" bgcolor = "#dce6f1"|365
 +
|align = "center" bgcolor = "#dce6f1"|[[Image:InLay_Optima.png|thumb|center|100px|<center>InLay Optima</center>]]
 +
|-
 +
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.bardurological.com/products/loadProduct.aspx?bUnitID=3&prodID=227 Bardex® Double Pigtail Soft Stent]</u></font>
 +
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=8912 FDA 510(k)]</u></font>
 +
|align = "center" bgcolor = "#dce6f1"|Jan, 2003
 +
|bgcolor = "#dce6f1"|Silicone
 +
|bgcolor = "#dce6f1"|Attached with suture for ease of removal
 +
|align = "center" bgcolor = "#dce6f1"|
 +
|align = "center" bgcolor = "#dce6f1"|[[Image:Bardex.png|thumb|center|100px|<center>Bardex</center>]]
 +
|-
 +
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.bardurological.com/products/loadProduct.aspx?bUnitID=3&prodID=228 Fluoro-4 Silicone Ureteral Stent]</u></font>
 +
|align = "center" bgcolor = "#dce6f1"|
 +
|align = "center" bgcolor = "#dce6f1"|
 +
|bgcolor = "#dce6f1"|Silicone/tantalum
 +
|bgcolor = "#dce6f1"|
 +
|align = "center" bgcolor = "#dce6f1"|
 +
|align = "center" bgcolor = "#dce6f1"|[[Image:Fluoro_4.png|thumb|center|100px|<center>Fluoro 4</center>]]
 +
|-
 +
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.bardurological.com/products/loadProduct.aspx?bUnitID=3&prodID=230 Figure-4 Silicone Ureteral Stent]</u></font>
 +
|align = "center" bgcolor = "#dce6f1"|
 +
|align = "center" bgcolor = "#dce6f1"|
 +
|bgcolor = "#dce6f1"|Silicone
 +
|bgcolor = "#dce6f1"|Three dimensional design
 +
|align = "center" bgcolor = "#dce6f1"|
 +
|align = "center" bgcolor = "#dce6f1"|[[Image:Figure_4.png|thumb|center|100px|<center>Figure 4</center>]]
 +
|-
 +
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.bardurological.com/products/loadProduct.aspx?bUnitID=3&prodID=226 InLay Ureteral Stent]</u></font>
 +
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=122796 FDA 510(k)]</u></font>
 +
|align = "center" bgcolor = "#dce6f1"|Dec, 1998
 +
|bgcolor = "#dce6f1"|Silicone
 +
|bgcolor = "#dce6f1"|Tapered tip and lubricious hydrophilic coating
 +
|align = "center" bgcolor = "#dce6f1"|
 +
|align = "center" bgcolor = "#dce6f1"|[[Image:InLay.png|thumb|center|100px|<center>InLay</center>]]
 +
|-
 +
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.bardurological.com/products/loadProduct.aspx?bUnitID=3&prodID=229 Urinary Diversion Stent]</u></font>
 +
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=86128 FDA 510(k)]</u></font>
 +
|align = "center" bgcolor = "#dce6f1"|Apr, 1991
 +
|bgcolor = "#dce6f1"|Silicone
 +
|bgcolor = "#dce6f1"|
 +
|align = "center" bgcolor = "#dce6f1"|
 +
|align = "center" bgcolor = "#dce6f1"|[[Image:Urinary_Diversion_Stent.png|thumb|center|100px|<center>Urinary Diversion Stent</center>]]
 +
|-
 +
|align = "center" rowspan = "4"|'''10'''
 +
|align = "center" rowspan = "4"|<font color="#0000FF">[http://www.coloplast.com/Pages/home.aspx Coloplast-Porges]</font>
 +
|align = "center"|<font color="#0000FF"><u>[http://www.porges.ru/catalog.html?cid=251 Vortek]</u></font>
 +
|align = "center"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=121312 FDA 510(k)]</u></font>
 +
|align = "center"|Oct, 1998
 +
|Silicone
 +
|Double coating for easy maneuverability as well as flexibility
 +
|align = "center"|
 +
|align = "center"|[[Image:Vortek.png|thumb|center|100px|<center>Vortek</center>]]
 +
|-
 +
|align = "center"|<font color="#0000FF"><u>[http://www.porges.ru/catalog.html?cid=248 Biosoft]</u></font>
 +
|align = "center"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=121312 FDA 510(k)]</u></font>
 +
|align = "center"|Oct, 1998
 +
|Silicone
 +
|Extreme flexibility
 +
|align = "center"|
 +
|align = "center"|[[Image:Biosoft.png|thumb|center|100px|<center>Biosoft</center>]]
 +
|-
 +
|align = "center"|<font color="#0000FF"><u>[http://www.porges.ru/catalog.html?cid=249 Polyurethane]</u></font>
 +
|align = "center"|
 +
|align = "center"|
 +
|Hard or soft Polyurethane
 +
|Designed for short-term use
 +
|align = "center"| 90
 +
|align = "center"|[[Image:Polyurethane1.png|thumb|center|100px|<center>Polyurethane</center>]]
 +
|-
 +
|align = "center"|<font color="#0000FF"><u>[http://www.porges.ru/catalog.html?cid=250 Silicone]</u></font>
 +
|align = "center"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=6586 FDA 510k)]</u></font>
 +
|align = "center"|Oct, 2002
 +
|Silicone
 +
|''Pyatiprofilnaya'' technology
 +
|align = "center"|
 +
|align = "center"|[[Image:Silicone1.png|thumb|center|100px|<center>Silicone</center>]]
 +
|-
 +
|align = "center" bgcolor = "#dce6f1"|'''11'''
 +
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF">[http://www.teleflex.com/en/emea/productAreas/urology/index.html Teleflex Medical]</font>
 +
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.google.com/url?sa=t&source=web&cd=3&ved=0CCQQFjAC&url=http%3A%2F%2Fwww.myrusch.com%2Fimages%2Frusch%2Fdocs%2FU62C.pdf&rct=j&q=DD%2Bureteral%2Bstent&ei=CcY-TeDWHcrirAfyr4naCA&usg=AFQjCNHSSc9r_DBwotSa_oszWLYMPRuoYg&cad=rja Rüsch Superglide DD]</u></font>
 +
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=122381 FDA 510(k)]</u></font>
 +
|align = "center" bgcolor = "#dce6f1"|Jul, 1999
 +
|bgcolor = "#dce6f1"| WIRUTHAN® (polyurethane) with hydrogel coating
 +
|bgcolor = "#dce6f1"| Directable and detachable
 +
|align = "center" bgcolor = "#dce6f1"|
 +
|align = "center" bgcolor = "#dce6f1"|[[Image:Superglide_DD.png|thumb|center|100px|<center>Superglide DD</center>]]
 +
|-
 +
|align = "center" rowspan = "9"|'''12'''
 +
|align = "center" rowspan = "9"|<font color="#0000FF">[http://www.gyrusacmi.com/user/display.cfm?display=cat_menu&maincat=Stone%20Management&catid=122 Gyrus ACMI/Cabot/Acromed/Circon/Surgitek]</font>
 +
|align = "center"|<font color="#0000FF"><u>[http://www.gyrusacmi.com/user/display.cfm?display=product&pid=9257&catid=122&maincat=Stone%20Management&catname=Stents Classic closed-tip]</u></font>
 +
|align = "center"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=68160 FDA 510(k)]</u></font>
 +
|align = "center"|Dec, 1986
 +
|
 +
|Classic Closed Tip
 +
|align = "center"|
 +
|align = "center"|[[Image:Gyrus_Closed_Tip.png|thumb|center|100px|<center>Classic Closed Tip</center>]]
 +
|-
 +
|align = "center"|<font color="#0000FF"><u>[http://www.gyrusacmi.com/user/display.cfm?display=product&pid=9252&catid=122&maincat=Stone%20Management&catname=Stents Classic Double pigtail]</u></font>
 +
|align = "center"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=111987 FDA 510(k)]</u></font>
 +
|align = "center"|Mar, 1996
 +
|Tecoflex® construction
 +
|Balanced-curled double pigtail design
 +
|align = "center"|
 +
|align = "center"|[[Image:Gyrus_Pigtail.png|thumb|center|100px|<center>Double Pigtail</center>]]
 +
|-
 +
|align = "center"|<font color="#0000FF"><u>[http://www.gyrusacmi.com/user/display.cfm?display=product&pid=9256&catid=122&maincat=Stone%20Management&catname=Stents Double-J]</u></font>
 +
|align = "center"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=74392 FDA 510(k)]</u></font>
 +
|align = "center"|Apr, 1988
 +
|Silicone
 +
|Double-J closed-tip
 +
|align = "center"|
 +
|align = "center"|[[Image:Gyrus_Double_J.png|thumb|center|100px|<center>Double_J</center>]]
 +
|-
 +
|align = "center"|<font color="#0000FF"><u>[http://www.gyrusacmi.com/user/display.cfm?display=product&pid=9254&catid=122&maincat=Stone%20Management&catname=Stents Lithostent]</u></font>
 +
|align = "center"|
 +
|align = "center"|
 +
|Tecoflex®
 +
|Grooved design
 +
|align = "center"|
 +
|align = "center"|[[Image:Lithostent.png|thumb|center|100px|<center>Lithostent</center>]]
 +
|-
 +
|align = "center"|<font color="#0000FF"><u>[http://www.gyrusacmi.com/user/display.cfm?display=product&pid=9253&catid=122&maincat=Stone%20Management&catname=Stents Lubri-flex]</u></font>
 +
|align = "center"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=91169 FDA 510(k)]</u></font>
 +
|align = "center"|Nov, 1991
 +
|Tecoflex®
 +
|“Rememberance” of shape with a chemically bonded wettable solution
 +
|align = "center"|
 +
|align = "center"|[[Image:Lubri_Flex.png|thumb|center|100px|<center>Lubri-flex</center>]]
 +
|-
 +
|align = "center"|<font color="#0000FF"><u>[http://www.gyrusacmi.com/user/display.cfm?display=product&pid=9250&catid=122&maincat=Stone%20Management&catname=Stents Multi-flex]</u></font>
 +
|align = "center"|
 +
|align = "center"|
 +
|Tecoflex®
 +
|Two durometers with helical kidney curls
 +
|align = "center"|
 +
|align = "center"|[[Image:Multi_Flex.png|thumb|center|100px|<center>Multi-flex</center>]]
 +
|-
 +
|align = "center"|<font color="#0000FF"><u>[http://www.gyrusacmi.com/user/display.cfm?display=product&pid=9255&catid=122&maincat=Stone%20Management&catname=Stents Quadra-Coil multi-length]</u></font>
 +
|align = "center"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=107077 FDA 510(k)]</u></font>
 +
|align = "center"|Mar, 1996
 +
|Tecoflex®
 +
|Accomodate ureteral lengths from 22cm to 28cm
 +
|align = "center"|
 +
|align = "center"|[[Image:Quadra_Coil.png|thumb|center|100px|<center>Quadra-Coil</center>]]
 +
|-
 +
|align = "center"|<font color="#0000FF"><u>[http://www.gyrusacmi.com/user/display.cfm?display=product&pid=9249&catid=122&maincat=Stone%20Management&catname=Stents Sof-curl]</u></font>
 +
|align = "center"|
 +
|align = "center"|
 +
|Tecoflex®
 +
|Dual-durometer design and exclusive soft bladder helix
 +
|align = "center"|
 +
|align = "center"|[[Image:Sof_curl.png|thumb|center|100px|<center>Sof-curl</center>]]
 +
|-
 +
|align = "center"|<font color="#0000FF"><u>[http://www.gyrusacmi.com/user/display.cfm?display=product&pid=9258&catid=122&maincat=Stone%20Management&catname=Stents Uroguide]</u></font>
 +
|align = "center"|
 +
|align = "center"|
 +
|Silicone
 +
|Classic Double J with open tip
 +
|align = "center"|
 +
|align = "center"|[[Image:Uroguide.png|thumb|center|100px|<center>Uroguide</center>]]
 +
|-
 +
|align = "center" bgcolor = "#dce6f1"|'''13'''
 +
|align = "center" bgcolor = "#dce6f1"|[http://www.amecath.com/ Ameco Medical Industries]
 +
|align = "center" bgcolor = "#dce6f1"|[http://www.amecath.com/ Amecath]
 +
|bgcolor = "#dce6f1"|
 +
|bgcolor = "#dce6f1"|
 +
|bgcolor = "#dce6f1"|Nitinol; Available with hydrophilic coating
 +
|bgcolor = "#dce6f1"|Double loop stent
 +
|align = "center" bgcolor = "#dce6f1"|Short-term and long-term
 +
|align = "center" bgcolor = "#dce6f1"|[[Image:Amecath.png|thumb|center|100px|<center>Amecath</center>]]
 +
|-
 +
|align = "center"|'''14'''
 +
|align = "center"|[http://www.zapconnect.com/companies/index.cfm/fuseaction/companies_detail/eregnum/9681442.html Angiomed-Movaco (C.R. Bard subsidiary)]
 +
|align = "center"|[http://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm?db=pmn&id=K864225 Ureteral Stent Set]
 +
|align = "center"|[http://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm?db=pmn&id=K864225 FDA 510(k)]
 +
|align = "center"|Jan, 1987
 +
|Nitinol
 +
|Self-expanding stent
 +
|
 +
|align = "center"|N/A
 +
|-
 +
|}
 +
 
 +
= Product to Clinical Trial Mapping=
 +
 
 +
==Clinical Timeline Visualization ==
 +
[[Image:Timeline.jpg]]
 +
 
 +
[[Media:Ureteral_Stents_Timeline dw.xls|Ureteral Stent Timeline]]
 +
 
 +
= Product to Patent Mapping =
 +
 
 +
[[Image:Product_Patent_Mapping_Screen_Shot.png|1000px|centre|thumb|'''Screenshot for the product to patent mapping(Bard and Boston)''']]
 +
* Click [[Media:Product_Patent_Mapping_Bard_Boston.xls|'''Products from Boston Scientific and C R Bard ''']]to download the excel file.
 +
== Mapped Patent vs Not Mapped Patents ==
 +
{|border="0" cellspacing="0" cellpadding="4" width="100%"
 +
|[[Image:CRB_Pat.png|center|500px|thumb|'''C R Bard''']]
 +
|[[Image:BS_pat.png.png|center|500px|thumb|'''Boston Scientific''']]
 +
|-
 +
|}
 +
 
 +
=Patent-Product-Clinical Trial Mapping=
 +
 
 +
* To access the Dashboard you have to signup. You can do so by clicking [https://www.dolcera.com/auth/index.php/login '''here''']
 +
*''Use the mouse(click and drag/scroll up or down/click on nodes) to explore nodes in the detailed taxonomy''
 +
*''Click on the red arrow adjacent to the node name to view the content for that particular node in the dashboard''
 +
*''Click on the "+" sign to zoom the mindmap and "-" sign to shrink the mindmap''
 +
{|border="2" cellspacing="0" cellpadding="4" width="100%"
 +
 
 +
|<mm>[[ureteral_stent_mapping1.mm|flash|Ureteral Stent mindmap|600pt]]</mm>
 +
 
 +
|}
 +
 
 +
=Insights=
 +
 
 +
{|border="2" cellspacing="0" cellpadding="4" width="100%"
 +
|bgcolor = "#538ED5"|<font size = "4">''' '''</font>
 +
|bgcolor = "#538ED5"|<font size = "4">''' '''</font>
 +
|bgcolor = "#538ED5"|<font size = "4">'''Boston Scientific'''</font>
 +
|bgcolor = "#538ED5"|<font size = "4">'''C R BARD'''</font>
 +
|-
 +
|align = "center" bgcolor = "#538ED5" rowspan = "4"|'''Products'''
 +
|'''Portfolio'''
 +
|8 Products
 +
|6 Products
 +
|-
 +
|'''Material'''
 +
|Percuflex - Biocompatible Polymer
 +
|Silicone
 +
|-
 +
|'''Coating'''
 +
|Hydroplus
 +
|Licensed from pHreecoat
 +
|-
 +
|'''Shape'''
 +
|Pigtailed and More
 +
|Figure 4 and more
 +
|-
 +
|align = "center" bgcolor = "#538ED5"|'''Clinical <br>Trials'''
 +
|'''Current Trials'''
 +
|Truimph Ureteral stent - Loaded with Triclosan <br>Currently in Phase II (Canada)
 +
|None
 +
|-
 +
|align = "center" bgcolor = "#538ED5" rowspan = "3"|'''Patents'''
 +
|'''Coating'''
 +
|Therapeutic / Medicinal coatings <br>Magnetic nano particles for MRI Imaging <br>Lubricious coatings helping easy insertion
 +
|Therapeutic coatings
 +
|-
 +
|'''Structure'''
 +
|Multiple channels filled with therapeutic agent<br>Multiple collapsible segments preventing fluid passing<br>Renal coil with wick to prevent reflux <br>Stent with beads on its surface <br>Stent with reservoir indicating its release <br>with change in color of urine<br>Expandable and collapsible stent<br>Stents with degradable barbs
 +
|Expandable stents for reducing  discomfort
 +
|-
 +
|'''Material'''
 +
|Elastically deformable stents<br>Biodegradable polymer based stents<br>Porous polymer for long term implantation<br>Stent with variable hardness
 +
|Biodegradable polymers<br>Shape memory alloys<br>General polymer based
 +
|-
 +
|}
 +
 
 +
 
 +
== Inference ==
 +
 
 +
{|border="2" cellspacing="0" cellpadding="4" width="82%"
 +
|bgcolor = "#538ED5"|<font size = "4">'''Boston Scientific'''</font>
 +
|bgcolor = "#538ED5"|<font size = "4">'''C R BARD'''</font>
 +
|-
 +
|Relatively late entrant with patents filed post mid 90s
 +
|Early mover with patents filed in mid 80s
 +
|-
 +
|Increased patent activity since 2000
 +
|Patent activity never gained traction
 +
|-
 +
|Large number of patents yet to be "productized"
 +
|Few patents yet to be "productized"
 +
|-
 +
|Some products undergoing clinical trails
 +
|No products undergoing clinical trails
 +
|-
 +
|Diverse range of products with variation in material <br>and structure
 +
|Small product portfolio
 +
|-
 +
|Seem to be strengthening they market position
 +
|Seem to be moving focus away from Ureteral stents market
 +
|-
 +
|}
 +
 
 +
= Competitive Landscape =
 +
==Major Players==
 +
*Boston Scientific Limited, Abbott, Medtronic and Cook Inc. are the major players in ureteral stent research field.
 +
[[Image:Major playersnew.jpg|thumb|center|1000px|Major Players]]
 +
 
 +
==IP Activity==
 +
*Patenting activity has been high growth rate during the period 2001 to 2005 with a peak no. of patents in year 2005, followed by saturation during the period 2006 to 2008 and after that a gradual declination upto year 2010 in the ureteral stent research area.
 +
[[Image:IPactivity3.png|thumb|center|1000px| IP activity over the years]]
 +
 
 +
==Sales ==
 +
 
 +
Total Sales in 2010 - 4.04 Billion USD
 +
 
 +
{|border="2" cellspacing="0" cellpadding="4" width="100%"
 +
|bgcolor = "#4f81bd"|'''Company'''
 +
|bgcolor = "#4f81bd"|'''Total Sales in 2010'''
 +
|bgcolor = "#4f81bd"|'''Urological sales'''
 +
|bgcolor = "#4f81bd"|'''Percentage share'''
 +
|bgcolor = "#4f81bd"|'''Product portfolio'''
 +
|-
 +
|bgcolor = "#4f81bd"|'''Boston Scientific'''
 +
|7800
 +
|661
 +
|8.48
 +
|<font color="#0000FF"><u>[http://www.bostonscientific.com/templatedata/imports/Microsite/Stone/collateral/Percuflex-Brochure.pdf Boston_portfolio]</u></font>
 +
|-
 +
|bgcolor = "#4f81bd"|'''CR BARD'''
 +
|2700
 +
|702
 +
|26.00
 +
|<font color="#0000FF"><u>[https://dolcera.net/teamwiki_prod/index.php/BARD_portfolio BARD_portfolio]</u></font>
 +
|-
 +
|bgcolor = "#4f81bd"|'''Cook Medical'''
 +
|1700
 +
|<nowiki>-</nowiki>
 +
|<nowiki>-</nowiki>
 +
|<font color="#0000FF"><u>[http://www.cookmedical.com/uro/familyListingAction.do?family=Ureteral+Stents Cook_portfolio]</u></font>
 +
|-
 +
|bgcolor = "#4f81bd"|'''Medline'''
 +
|4040
 +
|<nowiki>-</nowiki>
 +
|<nowiki>-</nowiki>
 +
|<font color="#0000FF"><u>[http://www.medline.com/irj/catalog/search?initialSearchTerms=ureteral%20stent Medline_portfolio]</u></font>
 +
|-
 +
|}
 +
 
 +
 
 +
[[image:stentshare.jpg |thumb|center|1000px| All figures in USD million ]]
 +
 
 +
=<span style="color:#C41E3A">Like this report?</span>=
 +
<p align="center"> '''This is only a sample report with brief analysis''' <br>
 +
'''Dolcera can provide a comprehensive report customized to your needs'''</p>
 +
{|border="2" cellspacing="0" cellpadding="4" align="center" "
 +
|style="background:lightgrey" align = "center"  colspan = "3"|'''[mailto:info@dolcera.com <span style="color:#0047AB">Buy the customized report from Dolcera</span>]'''
 +
|-
 +
| align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services Patent Analytics Services]
 +
|align = "center"| [http://www.dolcera.com/website_prod/services/business-research-services Market Research Services]
 +
|align = "center"| [http://www.dolcera.com/website_prod/tools/patent-dashboard Purchase Patent Dashboard]
 +
|-
 +
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Landscape Services]
 +
|align = "center"| [http://www.dolcera.com/website_prod/research-processes Dolcera Processes]
 +
|align = "center"| [http://www.dolcera.com/website_prod/industries Industry Focus]
 +
|-
 +
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Search Services]
 +
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/alerts-and-updates Patent Alerting Services]
 +
|align = "center"| [http://www.dolcera.com/website_prod/tools Dolcera Tools]
 +
|-
 +
|}
 +
<br>
  
−
Merrill Lynch and Steve Nordstrom, this number must be substantially
 
−
higher.
 
−
+ Ureteral stents are the standard of care even though the available stents
 
−
have issues of encrustation, fracturing and infection and need to be
 
−
replaced frequently.
 
−
3.2 Competitive Assessment
 
−
+ There are different types of ureteral stents on the market. Merrill
 
−
Lynch (May 2000) estimates that Boston Scientific is the leader with
 
−
-50% of the market followed by Maxxim (Circon), Cook and Bard
 
−
with the smallest share. There are other smaller players. Steve
 
−
Nordstrom estimates that Boston Scientific has 70% of the market.
 
−
+ There are various ureteral stent designs: Double J, Double Pig Tail,
 
−
Multi Coil, etc., some with hydrophilic coatings. Ureteral stents are
 
−
typically silicone, polyolefin or polyurethane. There are no FDA
 
−
approved antimicrobial ureteral stents. Europe?
 
−
+ We do not foresee alternative technologies that will replace the need
 
−
for ureteral stenting because it has various intraoperative and
 
−
postoperative indications. It was predicted that the number of stenting
 
−
procedures would decrease with ESWL, however, this does not seem
 
−
to be the case. The indications have actually broadened.
 
−
+ In general, encrustation and infection are the main problems
 
−
associated with all available ureteral stents.
 
−
+ See Appendix for a comparison of existing products (living document)
 
−
3.3 Value Price
 
−
+ In 1998, MDI estimated the current average selling price of ureteral
 
−
stents to be a p p r o x i m a t e l m Gore purchased stents from various
 
−
3 5 u ' t *r companies through the Science Center for approximately $1 50 each.
 
−
+.p QOaJ '. 4- Steve Nordstrom stated that the average sellin rices for the Boston
 
−
Scientific, Bard and Cook ureteral stents ar& $90 and $70,
 
−
3 1 6 respectively, with discounts.
 
−
7 ? - + + Bard increased the price of their Foley Catheters from- to ,with a
 
−
silver coating. We estimate that if the Gore ureteral stent were to add
 
−
value by improved encrustation and biofilm resistance, a- small increase could be commanded. s di A .-.L ? e-k LA&v 3+ &
 
−
+ According to estimates by Steve Nordstrom and John Brinkman, a ~ ;;+ s
 
−
corporate partner such as Boston Scientific, who makes ureteral stents
 
−
at approximatel&- would only pay more if our stent were
 
−
clearly superior to theirs.
 
−
+ At this time, it is premature to estimate the cost of a GORE stent due
 
−
to potential changes in process equipment and raw material cost.
 
−
4.0 Regulatory and Clinical Assessment
 
−
+ A new ureteral stent requires a 5 1 OK
 
−
+ We will propose a 5 1 OK with no clinical trial to FDA based on:
 
  
−
+ Safety and efficacy data in a pig model with histology of the
 
−
urothelium
 
−
+ Extensive PATT biocompatibility in PATT Master File
 
−
+ Antimicrobial performance to claim inhibition of bacterial
 
−
colonization of the devices for up to 2 weeks after implantation.
 
−
Sequential zone-of-inhibition assays will be conducted to show
 
−
substantial preservative activity against the following clinical isolates
 
−
of gram-positive and grarn-negative organisms: Candida sp.,
 
−
rb Citrobacter diversus, Enterobacter cloacae, Enterococcus, Escherichia
 
−
coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas
 
−
aeruginosa, Staphylococcus saprophyticus and Streptococcus fecalis.
 
−
+ It is possible FDA will require a clinical trial because of the antimicrobial
 
−
substances andlor because PATT is a new material for a ureteral stent
 
−
application.
 
−
+ If FDA requires a clinical trial, we believe it will be relatively short-term (3-6
 
−
months) and will require a relatively low number of patients (under 100).
 
−
5.0 Manufacturing Assessment
 
−
5.1 Process Technology- PATT-EXT (extrusion grade)
 
−
+ Tube extrusion-screw extrusion of PATT into catheter size tubes
 
−
+ Possible co-extrusion if filled material becomes necessary
 
−
+ Antimicrobial coating and filled technologies
 
−
5.2 Manufacturing Approach
 
−
+ The ureteral stent can be manufactured at Elk Hill
 
−
+ Capital requirements: existing equipment, possible scale-up and
 
−
additional equipment for antimicrobial incorporation
 
−
+ Greatest uncertainty to success in manufacturing: cost of final device,
 
−
$uy-c-timicrobial incorporation without affecting the mechanical
 
−
&J...bGs roperties of the overall device
 
−
5.3 Materials Strategy
 
−
+ Greatest uncertainty for success with materials: measurable difference
 
−
in efficacy in-vivo demonstrating that PATT + antimicrobial
 
−
technology meets performance criteria. -r iuhrd & ~ e ~ s + & r ?
 
−
oatarc+- -K-buh?
 
−
6.0 Risk Assessment M<~-A+ cld9XPU4+3yr
 
−
6.1 Probability of Project success exiting Phase 4: 80% s Ce-0 q
 
−
-
 
−
6.2 Critical assumptions
 
−
+ Key criteria that would trigger an interim review: toxicity in the - -
 
−
urinary tract, encrustation performance inferior to competition.
 
−
+ Technology (technology feasibility; IP protection; scale-up): safe and
 
−
efficacious in vivo; we can practice and are protected; we can scale-up
 
−
+ Market and competitive: we will partner with a major player
 
−
+ Manufacturing (costs; ramp-up; yields; sourcing): TBD
 
−
s i t e of
 
−
s+aK;C, + Project commitments (objectives; targets; resources): evaluation of
 
−
prototypes with antimicrobial, in vitro antimicrobial activity studies,
 
  
−
pig implant data, encrustation testing of comparative catheters, surface
+
=[[Backup]]=
−
lubricity tests (coefficient of friction); resources will include three fulltime
+
−
associates for engineering, NPD, project management and sales &
+
−
marketing.
+
−
6.3 Death Blow
+
−
+ In vitro tests show no difference in encrustation compared with
+
−
competitors
+
−
+ Toxicity in the urinary tract in pig model
+
−
+ Surgeons do not see value in a perfluoroelastomeric device and its
+
−
attributes
+
−
+ Lack of distribution partner (Phase 11)
+
−
+ Cost to manufacture is more than we could sell for
+
−
6.4 Plan to test Critical Assumptions and Death Blow
+
−
+ Prototypes with antimicrobial
+
−
+ ASTM encrustation model
+
−
+ In vivo safetyltoxicity study in pig
+
−
+ Understand surgical techniques
+
−
+ Survey surgeons
+
−
+ Develop strategy for alliance
+
−
+ Estimate costs to make device from synthesis to final device
+
−
6.5 Risks to Gore
+
−
+ A business partner is needed
+
−
+ It needs to be decided what our product offering will be: the catheter
+
−
only or the entire package (or something in between). Depending on
+
−
what is decided, this may have impact on our profitability.
+
−
+ No potential legal conflicts foreseen
+
−
7.0 Project Plan
+
−
7.1 Phase I Plan
+
−
+ Objectives and deliverables:
+
−
+ Detailed Plan
+
−
+ Understand surgical procedures
+
−
+ Survey surgeons
+
−
+ + Prototypes with antimicrobials
+
−
+ Antimicrobial elution study
+
−
-b *4 + In vitro antimicrobial testing (zones of inhibition)
+
−
-it&-
+
−
pe++de"". + Mechanical and surface testing (tensile, elongation, etc. according
+
−
to Draft Guidance; coefficient of friction, surface energy, etc.)
+
−
+ In vitro encrustation further testing A S~L+S&.?
+
−
+ Animal experiment (pig) toxicity in urinary tract; toxicity to
+
−
urinary mucosa
+
−
+ Critical Path: same as above
+
−
+ Milestones: same as above
+
−
7.2 Core Team
+
−
+ Cindy Eaton, Thane Kranzler, Ruth Cutright?, Norman Pih
+

Latest revision as of 05:45, 27 July 2015

This is a landscape report on the Ureteral stent market, including key company profiles, products, patents and relevant clinical trials.

  • What is it? A ureteral stent is a specially designed hollow tube, made of a flexible plastic material that is placed in the ureter.
  • Need for a ureteral stent: In patients who have, or might have, an obstruction (blockage) of the kidney, an internal drainage tube called a ‘stent’ is commonly placed in the ureter, the tube between the kidney and the bladder. This is placed there in order to prevent or temporarily relieve the obstruction.

Background

Ureteric Stent

Ureteral stents are used in urological surgery to maintain patency of the ureter to allow urine drainage from the renal pelvis to the bladder. These devices can be placed by a number of different endourological techniques. They are typically inserted through a cystoscope and may also be inserted intraoperatively. Indwelling ureteral stents help to reduce complications and morbidity subsequent to urological and surgical procedures. Frequently, ureteral stents are used to facilitate drainage in conjunction with Extracorporeal Shock Wave Lithotripsy (ESWL) and after endoscopic procedures. They are also used to internally support anastomoses and prevent urine leakage after surgery. Ureteral stenting may almost eliminate the urological complications of renal transplantation. An antimicrobial ureteral stent, which inhibits encrustation and bacterial colonization while maintaining patient comfort.

  • Ureteral stent: resists migration, resists fragmentation, is kink resistant and radiopaque.
  • Bacterial colonization: antimicrobial activity for up to two weeks.
  • Patient Comfort: stent has a low coefficient of friction (value) for ease of insertion and will soften on implant at body temperature to maintain patient comfort.

more on background...

Market Overview

Market for ureteral stent can be analyzed by estimating market for each of Ureteral Stent’s fundamental use. Other uses of Ureteral Stent include Post-surgical swelling/infection of uterus, Active kidney infection etc.

more on market overview...

Interactive Mind Map

  • To access the Dashboard you have to signup. You can do so by clicking here
  • Use the mouse(click and drag/scroll up or down/click on nodes) to explore nodes in the detailed taxonomy
  • Click on the red arrow adjacent to the node name to view the content for that particular node in the dashboard
  • Click on the "+" sign to zoom the mindmap and "-" sign to shrink the mindmap

Patents

Patent Search Strategy

Patent Search Strategy.jpg


Dolcera Dashboard

Dashboard Link

Ureteral Stent - Dashboard
Dashboard thumb.png
  • Flash Player is essential to view the Dolcera Dashboard
  • To access the Dashboard you have to signup. You can do so by clicking here

Clinical Trials

New trials

S.No.
Title
Conditions
Intervention: Device
Sponsors and Collaborators
1
 Assessment of Drug-Eluting Ureteral Stent on Bacterial Adherence and Biofilm Formation Renal Calculi, Ureteral Obstruction Ureteral Stent Lawson Health Research Institute, Boston Scientific Corporation
2
 Memokath® 044TW Stent for Treatment of Urethral Stricture Urethral Stricture Memokath stenting Engineers & Doctors Wallsten Medical Group
3
 Study to Determine if There Are Specific Clinical Factors to Determine Stent Encrustation Kidney Stones N\A University of California, Irvine
4
 Ureteral Stent Length and Patient Symptoms Kidney Stones Ureteral Stent Emory University
5
 Drainage of Malignant Extrinsic Ureteral Obstruction Using the Memokath Ureteral Stent Ureteral Obstruction Memokath 051 Ureteral Stent Mayo Clinic Engineers & Doctors Wallsten Medical Group
6
 A Prospective Comparison Between Ureteral Stent and Nephrostomy Tube for an Urgent Drainage of Obstructed Kidney (JJVsPCN08) Kidney Disease Nephrostomy tube and ureteral stent Rabin Medical Center

Concluded trials

S.No.
Title
Abstract
Enrollment
Disorder
Conclusion
1
 Long-term outcome of permanent urethral stents in the treatment of detrusor-sphincter dyssynergia To evaluate the long-term efficacy of a permanently implanted urethral stent in the treatment of spinally injured patients with detrusor-sphincter dyssynergia. 13 Detrusor-sphincter dyssynergia Stenting is an effective alternative to sphincterotomy in the long-term, although secondary bladder neck obstruction is a frequent problem.
2
 Nephrostomy Tube or 'JJ' Ureteric Stent in Ureteric Obstruction: Assessment of Patient Perspectives Using Quality-of-Life Survey and Utility Analysis Upper urinary tract obstruction is often relieved by either a percutaneous nephrostomy tube (PCN) or a ureteric stent. Both can cause considerable morbidity and reduce patient's health-related quality of life (QoL). We have compared the QoL in these 2 groups. 34 Upper urinary tract obstruction Patients with 'JJ' stents have significantly more irritative urinary symptoms and a high chance of local discomfort than patients with nephrostomy tubes (PCN). However, based on the EuroQol analysis, there is no significant difference in the gross impact on the health-related QoL or the utility between these groups indicating no patient preference for either modality of treatment.
3
 Impact of stents on urological complications and health care expenditure in renal transplant recipients: results of a prospective, randomized clinical trial. A randomized, prospective trial to compare the incidence of early urological complications and health care expenditures in renal transplant recipients with or without ureteral stenting. 201 Renal transplant recipient Using a ureteral stent at renal transplantation significantly decreases the early urinary complications of urine leakage and obstruction. However, there is a significant increase in urinary tract infections, primarily beyond 30 days after transplantation. Stent removal within 4 weeks of insertion appears advisable.


Pre-Market Notification

Some of the companies active in the field of ureteral stents have been represented in the table below.

S.No.
Company
Device
Approval
Date of Approval
Material
Technology
Indwelling Time (days)
1
Bard Urological
InLay Optima
FDA 510(k)
Dec 2004
 Silicone Double pigtail with monofilament suture loop
365
2
Boston Scientific
Polaris Loop
FDA 510(k)
Mar 2003
 Dual Durometer Percuflex with HydroPlus Coating Bladder loop design
365
3
Cook Medical
Resonance
FDA 510(k)
May 2007
 Metal Temporary stenting
365
4
Fossa Medical
Stone Sweeper
FDA 510(k)
Aug 2002
 Polyurethane Spiral radially expanding stent
13
CE Mark
Sep 2005
5
Pnn Medical A/S
Memokath 051
CE Mark
1995
 Nickel-titanium shape memory alloy Double fluted ended spiral stent
240

Products

The FDA classifies a ureteric stent as follows:

  • TITLE 21 - FOOD AND DRUGS
  • CHAPTER I - FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES
  • SUBCHAPTER H - MEDICAL DEVICES
  • PART 876 - GASTROENTEROLOGY-UROLOGY DEVICES
  • Subpart E - Surgical Devices
  • Sec. 876.4620 - Ureteral stent.
  • Classification - class II device Code of Federal Regulations
Sr. No. Company Device(s) Approval Approval Date Material Technology Indwelling Time (days) Image
1 Allium, Israel URS CE Mark Jul, 2007 Nickel-titanium shape memory alloy covered by polymer Self-expanding stent
Allium
2 Pnn Medical A/S Memokath 051 CE Mark 1995 Nickel-titanium shape memory alloy Double fluted ended spiral stent 240
Memokath 051
FDA Listing Mar, 2004
3 Fossa Medical Stone Sweeper CE Mark Sep, 2005 Polyurethane Radially expanding stent 13
Stone Sweeper
FDA 510(k) Aug, 2002
Open lumen stent FDA 510(k) Nov, 2003 Polyurethane Pigtail-tipped stent with ’Pusher’
Open_lumen
CE Mark Sep, 2005
Expanding Ureteral Stent FDA 510(k) Jun, 2002 Polyurethane Double pigtail stent with ’Pusher’ N/A
4 Boston Scientific Contour Percuflex - proprietary polyolefin copolymer; Hydroplus coating Fixed and variable length; Tapered tip 365
Contour
Percuflex Percuflex Pigtail 365
Percuflex
Polaris Ultra FDA 510(k) Jan, 2001 Dual Durometer Percuflex with HydroPlus Coating; soft Nautilus Bladder Coil. Double pigtail 365
Polaris Ultra
Polaris Loop FDA 510(k) Mar, 2003 Dual Durometer Percuflex with HydroPlus Coating Bladder loop design 365
Polaris Loop
Retromax Plus Percuflex material and Hydroplus coating Endopyelotomy stent Post-procedure healing
Retromax Plus
Stretch VL Flexima Hydroplus Coating Variable length coil on distal and proximal ends 90
Stretch VL Flexima
Drug-Eluting Stent Percuflex - proprietary polyolefin copolymer Ketorolac trimethamine loaded stent N/A
5 Cook Medical Resonance FDA 510(k) May, 2007 Metal 365
Resonance
Sof-flex AQ® Hydrophilic Coating Radiopaque tip and tether for repositioning 180
Sof-flex
Endo-Sof AQ® Hydrophilic Coating Double pigtail 365
Endo-Sof
C-Flex Double Pigtail 180
C-Flex
Smith Universal Nephrostomy tube + Ureteral stent 60
Smith Universal
Endo-Sof Radiance Launch Dec, 2007 Heparin-bonded stent
6 Q Urological pAguaMedicina™ Pediatric Ureteral Stent FDA 510(k) Jan, 2010 Hydrogel Differentially larger end (no pigtail) 30
pAguaMedicina
7 Bioteque Corp. Ureteral Stent Set FDA 510(k) Apr, 2010 30
Bioteque
8 Applied Medical Resources, CA, USA Mesh FDA 510(k) Jul, 2001 Polyester mesh Double-pigtail N/A
Silhouette Coil-reinforced; SL-6® hydrophilic coating Patency Device
Silhouette
Applied Standard FDA 510(k) Jun, 1999 Proprietary thermoplastic elastomer material; SL-6® hydrophilic coating Unique wall construction and enlarged drainage holes
Applied Standard
7-10 endopyelotomy Proprietary thermoplastic elastomer material; SL-6® hydrophilic coating Dual Diameter stent
Endopyelotomy Stent
9 Bard Urological InLay Optima FDA 510(k) Dec, 2004 Silicone Double pigtail with monofilament suture loop 365
InLay Optima
Bardex® Double Pigtail Soft Stent FDA 510(k) Jan, 2003 Silicone Attached with suture for ease of removal
Bardex
Fluoro-4 Silicone Ureteral Stent Silicone/tantalum
Fluoro 4
Figure-4 Silicone Ureteral Stent Silicone Three dimensional design
Figure 4
InLay Ureteral Stent FDA 510(k) Dec, 1998 Silicone Tapered tip and lubricious hydrophilic coating
InLay
Urinary Diversion Stent FDA 510(k) Apr, 1991 Silicone
Urinary Diversion Stent
10 Coloplast-Porges Vortek FDA 510(k) Oct, 1998 Silicone Double coating for easy maneuverability as well as flexibility
Vortek
Biosoft FDA 510(k) Oct, 1998 Silicone Extreme flexibility
Biosoft
Polyurethane Hard or soft Polyurethane Designed for short-term use 90
Polyurethane
Silicone FDA 510k) Oct, 2002 Silicone Pyatiprofilnaya technology
Silicone
11 Teleflex Medical Rüsch Superglide DD FDA 510(k) Jul, 1999 WIRUTHAN® (polyurethane) with hydrogel coating Directable and detachable
Superglide DD
12 Gyrus ACMI/Cabot/Acromed/Circon/Surgitek Classic closed-tip FDA 510(k) Dec, 1986 Classic Closed Tip
Classic Closed Tip
Classic Double pigtail FDA 510(k) Mar, 1996 Tecoflex® construction Balanced-curled double pigtail design
Double Pigtail
Double-J FDA 510(k) Apr, 1988 Silicone Double-J closed-tip
Double_J
Lithostent Tecoflex® Grooved design
Lithostent
Lubri-flex FDA 510(k) Nov, 1991 Tecoflex® “Rememberance” of shape with a chemically bonded wettable solution
Lubri-flex
Multi-flex Tecoflex® Two durometers with helical kidney curls
Multi-flex
Quadra-Coil multi-length FDA 510(k) Mar, 1996 Tecoflex® Accomodate ureteral lengths from 22cm to 28cm
Quadra-Coil
Sof-curl Tecoflex® Dual-durometer design and exclusive soft bladder helix
Sof-curl
Uroguide Silicone Classic Double J with open tip
Uroguide
13 Ameco Medical Industries Amecath Nitinol; Available with hydrophilic coating Double loop stent Short-term and long-term
Amecath
14 Angiomed-Movaco (C.R. Bard subsidiary) Ureteral Stent Set FDA 510(k) Jan, 1987 Nitinol Self-expanding stent N/A

Product to Clinical Trial Mapping

Clinical Timeline Visualization

Timeline.jpg

Ureteral Stent Timeline

Product to Patent Mapping

Screenshot for the product to patent mapping(Bard and Boston)

Mapped Patent vs Not Mapped Patents

C R Bard
Boston Scientific

Patent-Product-Clinical Trial Mapping

  • To access the Dashboard you have to signup. You can do so by clicking here
  • Use the mouse(click and drag/scroll up or down/click on nodes) to explore nodes in the detailed taxonomy
  • Click on the red arrow adjacent to the node name to view the content for that particular node in the dashboard
  • Click on the "+" sign to zoom the mindmap and "-" sign to shrink the mindmap

Insights

Boston Scientific C R BARD
Products Portfolio 8 Products 6 Products
Material Percuflex - Biocompatible Polymer Silicone
Coating Hydroplus Licensed from pHreecoat
Shape Pigtailed and More Figure 4 and more
Clinical
Trials 		Current Trials Truimph Ureteral stent - Loaded with Triclosan
Currently in Phase II (Canada) 		None
Patents Coating Therapeutic / Medicinal coatings
Magnetic nano particles for MRI Imaging
Lubricious coatings helping easy insertion 		Therapeutic coatings
Structure Multiple channels filled with therapeutic agent
Multiple collapsible segments preventing fluid passing
Renal coil with wick to prevent reflux
Stent with beads on its surface
Stent with reservoir indicating its release
with change in color of urine
Expandable and collapsible stent
Stents with degradable barbs 		Expandable stents for reducing discomfort
Material Elastically deformable stents
Biodegradable polymer based stents
Porous polymer for long term implantation
Stent with variable hardness 		Biodegradable polymers
Shape memory alloys
General polymer based


Inference

Boston Scientific C R BARD
Relatively late entrant with patents filed post mid 90s Early mover with patents filed in mid 80s
Increased patent activity since 2000 Patent activity never gained traction
Large number of patents yet to be "productized" Few patents yet to be "productized"
Some products undergoing clinical trails No products undergoing clinical trails
Diverse range of products with variation in material
and structure 		Small product portfolio
Seem to be strengthening they market position Seem to be moving focus away from Ureteral stents market

Competitive Landscape

Major Players

  • Boston Scientific Limited, Abbott, Medtronic and Cook Inc. are the major players in ureteral stent research field.
Major Players

IP Activity

  • Patenting activity has been high growth rate during the period 2001 to 2005 with a peak no. of patents in year 2005, followed by saturation during the period 2006 to 2008 and after that a gradual declination upto year 2010 in the ureteral stent research area.
IP activity over the years

Sales

Total Sales in 2010 - 4.04 Billion USD

Company Total Sales in 2010 Urological sales Percentage share Product portfolio
Boston Scientific 7800 661 8.48 Boston_portfolio
CR BARD 2700 702 26.00 BARD_portfolio
Cook Medical 1700 - - Cook_portfolio
Medline 4040 - - Medline_portfolio


All figures in USD million

Like this report?

This is only a sample report with brief analysis
Dolcera can provide a comprehensive report customized to your needs

Buy the customized report from Dolcera
Patent Analytics Services Market Research Services Purchase Patent Dashboard
Patent Landscape Services Dolcera Processes Industry Focus
Patent Search Services Patent Alerting Services Dolcera Tools



Backup

Retrieved from "https://www.dolcera.com/wiki/index.php?title=Ureteral_Stent&oldid=11098"